PRECISIONheor
PRECISIONheor is a New York-based health economics and outcomes research consulting firm that generates HEOR evidence and payer strategy for pharmaceutical and biotech companies. It operates within Precision Medicine Group alongside Precision AQ, serving enterprise clients across multiple therapeutic areas including oncology and rare disease.
- Company typePrivate
- Founded2007
- HeadquartersNew York, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What PRECISIONheor does
PRECISIONheor is a New York-based health economics and outcomes research (HEOR) consulting firm founded in 2007, operating with 51-100 employees. Its core function is generating HEOR evidence and designing payer strategy and payer marketing programs that help pharmaceutical and biotech clients navigate payer complexity and optimize commercial success for new and existing therapies. The firm is part of the broader Precision Medicine Group, sitting alongside sister brand Precision AQ, which together offer an integrated agency-of-record platform spanning value and access, medical communications, investor relations, brand strategy, and data analytics. Within this ecosystem, PRECISIONheor provides the HEOR evidence-generation and access-strategy backbone, complemented by proprietary analytics products (AccessGenius, OncoGenius, Data Solutions, EHR Solutions, Omnichannel Solutions) that operationalize market potential evaluation and targeting across therapeutic areas including Oncology, Rare Disease, Immunology, Neurology, and Cardio Renal Metabolic.
Revenue mechanics are professional services-based: engagements are quote-based and project or retainer driven, sold through enterprise sales targeting commercial leaders at top pharmaceutical and biotech companies. The go-to-market is enterprise and field-led, with teams embedded within client commercialization organizations as an extension of internal functions rather than transactional vendor relationships. Select evidence of scale includes support for FDA drug launches in 2024 and an international footprint covering the US and UK. Pricing is not publicly disclosed, and no funding rounds, public listings, or revenue figures were identified in the source data, indicating a privately held, profitable-services operating posture under the Precision Medicine Group parent.
PRECISIONheor firmographics
Firmographics- Name
- PRECISIONheor
- Legal name
- Precision AQ
- Website
- https://precisionheor.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- PRECISIONheor is a New York-based health economics and outcomes research consulting firm that generates HEOR evidence and payer strategy for pharmaceutical and biotech companies. It operates within Precision Medicine Group alongside Precision AQ, serving enterprise clients across multiple therapeutic areas including oncology and rare disease.
- Ownership category
- akta.pro rank
PRECISIONheor industry classification
Industry- Product category
- HEOR Consulting
- NAICS
- Professional, Scientific, and Technical Services (541), Scientific Research and Development Services (5417), Marketing Consulting Services (541613)
- akta.pro primary industry
- Health Economics & Outcomes Research (HEOR) (HLAIAKAB)
- akta.pro secondary industries
- Real-World Evidence (RWE) & HEOR for Development (HLAIALAI), Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN)
Keywords
Where PRECISIONheor is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
PRECISIONheor business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Professional Services - Agency of Record: Precision AQ operates as an agency of record providing integrated services across market access, HEOR, medical communications, investor relations, and brand strategy. Revenue is generated through consulting engagements, retainer agreements, and project-based professional services for pharmaceutical and biotech commercialization needs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
PRECISIONheor product offering
Product offeringCore offering
PRECISIONheor is a health economics and outcomes research (HEOR) consulting firm that generates economic, clinical, and real-world evidence to support market access, payer strategy, and reimbursement decisions for pharmaceutical and biotech therapies. The firm operates within the Precision AQ commercialization platform, combining HEOR expertise with broader value-and-access, data analytics, and payer-marketing capabilities to help drug developers navigate payer complexity and optimize commercial success.
Product overview
Precision AQ is a multi-solution platform providing integrated services and technology products for pharmaceutical and biotech commercialization. The product portfolio includes five core offerings: AccessGenius (market access data solution), Data Solutions (patient/payer/provider analytics), EHR Solutions (electronic health record integration), Omnichannel Solutions (multi-channel engagement), and OncoGenius (oncology-specific analytics). These products are complemented by service divisions covering Value & Access (including HEOR, Access Consulting, Market Access Agency), Medical Communications (Peer-to-Peer Marketing, Medical Affairs, Learning & Development), Investor Relations & External Communications, Brand Strategy & Marketing, and Data Insights & Analytics. The platform spans four therapeutic areas: Immunology, Neurology, Oncology, and Rare Disease, with Cardio Renal Metabolic as an additional focus area.
Differentiator
Problem solved
Functional benefit
Brands
- AccessGenius: Product offering for market access solutions
- OncoGenius
- Data Solutions
- EHR Solutions
- Omnichannel Solutions
Products and services
- HEOR Consulting A consulting service that develops HEOR evidence (economic modeling, real-world data research, outcomes analysis) to help pharmaceutical and biotech clients demonstrate product value to payers and support market access.
- Value & Access Services An integrated service offering that combines HEOR evidence generation, payer strategy, and market access support to help drug developers navigate payer complexity and optimize commercial success.
- Access Consulting A consulting service that develops payer strategy and payer marketing plans to support market access and reimbursement for pharmaceutical and biotech therapies.
Quantifiable outcome
- Supported a percentage of all FDA-approved drugs launched in 2024
Companies that use PRECISIONheor
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles2 records
PRECISIONheor technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
PRECISIONheor partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights4 records
PRECISIONheor competitors and assessment
Company assessmentDirect peers
- Evidera: Evidera is a dedicated HEOR, market access, and real-world evidence consulting firm (now part of PPD/Thermo Fisher), serving the same pharma and biotech customers with overlapping value, access, and evidence-generation services — directly comparable to PRECISIONheor's core offering.
- Xcenda: Xcenda is a market access, HEOR, and reimbursement consulting firm (part of Cencora/AmerisourceBergen) that provides payer strategy, health economics, and real-world evidence services to pharma manufacturers — a direct peer in the same HEOR advisory space.
- Charles River Associates (CRA Health Economics & Market Access): CRA's Life Sciences practice delivers HEOR, market access, pricing, and evidence-based consulting to pharma and biotech clients — directly comparable to PRECISIONheor's payer strategy and health economics work.
- Analysis Group: Analysis Group is a consulting firm with a large health economics and outcomes research practice serving pharma, biotech, and medical device clients — closely matching PRECISIONheor's HEOR consulting model and customer base.
- Trinity Life Sciences: Trinity Life Sciences provides commercial strategy, market access, HEOR, and real-world evidence consulting to pharma and biotech — overlapping directly with Precision AQ's payer strategy, value & access, and evidence generation offerings.
Broad incumbents
- IQVIA: IQVIA is the largest healthcare data, analytics, and consulting platform, offering HEOR, real-world evidence, and market access services alongside clinical research and commercial solutions — a broad incumbent that overlaps heavily with Precision AQ's payer strategy and evidence-generation work.
- Syneos Health: Syneos Health is a large biopharmaceutical solutions organization combining clinical development with commercialization and market access consulting — directly competing for the same pharma AOR and commercialization engagements as Precision AQ.
- Parexel International: Parexel is a global CRO with dedicated market access, HEOR, and commercialization consulting capabilities, serving the same pharma/biotech client base and competing for integrated commercialization engagements.
- ZS Associates: ZS Associates is a global consulting firm with deep pharma commercial and market access practices, advising the same top-pharma commercial leaders that Precision AQ targets as AOR clients.
- Decision Resources Group (Clarivate): Decision Resources Group (now part of Clarivate) provides market access insights, epidemiology, and HEOR data and advisory services to pharma — adjacent peer delivering evidence and payer analytics that compete for similar budget allocations.
Market position
Strengths5 records
Weaknesses3 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
PRECISIONheor social profiles
Digital presencePRECISIONheor financial estimates
Financial estimateRevenue estimate
Valuation estimate
PRECISIONheor leadership team
Management profileNumber of profiles
PRECISIONheor funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PRECISIONheor M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PRECISIONheor
What does PRECISIONheor do?
PRECISIONheor is a health economics and outcomes research (HEOR) consulting firm that generates economic, clinical, and real-world evidence to support market access, payer strategy, and reimbursement decisions for pharmaceutical and biotech therapies. The firm operates within the Precision AQ commercialization platform, combining HEOR expertise with broader value-and-access, data analytics, and payer-marketing capabilities to help drug developers navigate payer complexity and optimize commercial success.
Is PRECISIONheor a public or private company?
PRECISIONheor is a private company. It is classified as corporate owned and is currently operating.
When was PRECISIONheor founded?
PRECISIONheor was founded in 2007. It employs 51 to 100 people.
Where is PRECISIONheor based?
PRECISIONheor is headquartered in New York, United States, in the North America region.
How does PRECISIONheor make money?
One revenue line is on record: professional Services - Agency of Record.
Who are PRECISIONheor's main competitors?
Direct peers on record are Evidera, Xcenda, Charles River Associates (CRA Health Economics & Market Access), Analysis Group and Trinity Life Sciences. Broad incumbents are IQVIA, Syneos Health, Parexel International, ZS Associates and Decision Resources Group (Clarivate).
Does PRECISIONheor have an API?
No public API is recorded for PRECISIONheor.
What industry is PRECISIONheor in?
PRECISIONheor's product category is HEOR Consulting. Its primary akta.pro industry code is HLAIAKAB, Health Economics & Outcomes Research (HEOR), with a secondary code of HLAIALAI, Real-World Evidence (RWE) & HEOR for Development. Its NAICS code is 541.